Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...

Gvoke for subcutaneous injection is only available as a brand-name drug. It doesn’t come in a generic version. However, glucagon (the active drug in Gvoke) is available in generic forms for ...

The product – which has been approved under the Gvoke brand name – is the ... It has been approved in prefilled syringe and pen injector formats. Glucagon has the opposite effect of insulin ...

Xeris has 3-4 approved products; these are: Gvoke (glucagon injection): Gvoke is the first autoinjector for severe hypoglycemia approved by the FDA. Keveyis (dichlorphenamide): The first FDA ...

Kevin McCulloch, Xeris’s President and COO, expressed enthusiasm for the FDA approval and the partnership, highlighting the potential of Gvoke VialDx™ to modernize glucagon administration for ...

The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the ...

Another drugs that may be used off-label for GHI include Xeris' Gvoke brand of glucagon in pre-filled syringe and pen injector formulations, which was approved in 2019 as a hypoglycaemia rescue ...

Kevin McCulloch, Xeris’s President and COO, expressed enthusiasm for the FDA approval and the partnership, highlighting the potential of Gvoke VialDx™ to modernize glucagon administration for ...